Table 2.
Chemotherapy‐associated fold changes in cfDNA concentration and Mean% changes in tumor SUVmax
| Patient | Baseline cfDNA level (ng/mL) | Fold change in cfDNA after 1 Cycle | Fold change in cfDNA after 3 Cycles | Change in mean tumor SUVmax after 1 Cycle | Change in mean tumor SUVmax after 3 Cycles | Sites of malignancy identified on FCH PET/CT |
|---|---|---|---|---|---|---|
| 1 | 8 | 6.6 | 11.3 | −18% | −42% | S |
| 2 | 7 | 21.2 | 8.5 | −48% | −66% | S |
| 3 | 19 | 1.9 | 0.8 | 11% | −24% | S |
| 4 | 14 | 1.6 | 4.7 | −9% | −24% | S, L |
| 5 | 14 | 3.3 | 3.8 | −3% | −23% | S |
| 6 | 10 | 1.2 | 2.3 | 3% | −29% | S |
| 7 | 25 | 1.0 | 2.6 | 2% | −7% | S, P |
| 8 | 9 | 3.0 | 3.5 | −34% | −37% | L |
For malignant sites identified by FCH PET/CT, S = skeletal system, L = lymph nodes, and P = prostate.